Abstract Introduction: Urothelial carcinoma (UC) is a molecularly heterogeneous disease, and transcriptome-based classification systems have given important insights into its biology. The current consensus classifications for UC represent a major step toward biological stratification; however, its prognostic and predictive relevance remains uncertain, limiting use in clinical guidelines. Furthermore, most molecular schemes have been developed either for non-muscle invasive (NMIBC) or muscle-invasive disease (MIBC), relying only on bulk transcriptomic data. This fragmentation hinders comparability across studies and integration with proteomic or single-cell datasets. A simplified molecular framework is therefore needed to capture UC heterogeneity more comprehensively and to support personalized therapeutic approaches. Materials Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6869.
Creij et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: